Lacnotuzumab

Modify Date: 2024-11-01 22:25:43

Lacnotuzumab structure	Common Name	Lacnotuzumab
	CAS Number	1831128-32-5	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Lacnotuzumab

Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].

Name	Lacnotuzumab

Description	Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Metabolic Disease Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Fms
Target	CSF-1[1]
In Vivo	Lacnotuzumab 中和食蟹猴重组和血清衍生形式的 CSF-1，但它不识别啮齿动物或兔的 CSF-1[2]。
References	[1]. Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115. [2]. Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.

No Any Chemical & Physical Properties

Lacnotuzumab

Use of Lacnotuzumab

Names

Lacnotuzumab Biological Activity

Chemical & Physical Properties